Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

Purpose: To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. Methods: We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. Results: Ten patients were included in the study. Two patients achieved a p...

Full description

Bibliographic Details
Main Authors: Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
renal medullary carcinoma
bevacizumab
erlotinib
platinum-based chemotherapy
aerobic glycolysis
Online Access:https://www.mdpi.com/2072-6694/13/9/2170

Internet

https://www.mdpi.com/2072-6694/13/9/2170

Similar Items